688578 Shanghai Allist Pharmaceuticals Co., Ltd.
- 57.77
- +0.11+0.19%
Shanghai Allist Pharmaceuticals Co., Ltd. News
Alice (688578.SH) 2023 equity distribution: $0.40 per share, share registration on May 30
According to Zhitong Finance App News, Alice (688578.SH) issued the 2023 equity distribution implementation notice. The profit distribution is based on the company's total share capital before implementation of the plan, with a cash dividend of 0.40 yuan (tax included) per share. The share registration date is May 30, 2024, and the exclusion (interest) date is May 31, 2024.
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Top Owners Are Private Companies With 44% Stake, While 28% Is Held by Individual Investors
Key Insights Shanghai Allist Pharmaceuticals' significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public 51% of the business is hel
Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination With Shanghai Allist's Furmonertinib
Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics said its investigational non-small cell lung cancer drug ABSK043 would be clinically tested in combination with Furmonertinib Mesilate Tablets, acco
Heyu-B (02256.HK): Carrying out clinical research on ABSK043 combined with vometinib mesylate tablets to treat advanced non-small cell lung cancer
On May 9, Ge Longhui (02256.HK) announced that ABSK043, an oral small molecule PD-L1 inhibitor developed by it, will soon conduct clinical research on combination treatment for advanced non-small cell lung cancer with vometinib mesylate tablets (trade name: Avsha, “vometinib”) independently developed by Allis (688578.SH).
Alice (688578.SH): Net profit in 2023 increased 393.54% year-on-year, and plans to pay 10 to 4 yuan
On April 25, Ge Longhui (688578.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 2,018 billion yuan, an increase of 155.14%; net profit attributable to shareholders of listed companies was 644 million yuan, an increase of 393.54%; net profit attributable to shareholders of listed companies deducted non-recurring profit and loss of 606 million yuan, an increase of 663.70% year on year; basic income per share was 1.43 yuan/share. It is proposed to distribute a cash dividend of $4.00 (tax included) for every 10 shares.
Some Confidence Is Lacking In Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) P/E
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) price-to-earnings (or "P/E") ratio of 33.3x might make it look like a sell right now compared to the market in China, where around half of th
Is Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Latest Stock Performance A Reflection Of Its Financial Health?
Most readers would already be aware that Shanghai Allist Pharmaceuticals' (SHSE:688578) stock increased significantly by 15% over the past three months. Given the company's impressive performance, w
Alice (688578.SH): AST2169 liposome for injection obtained approval notice for drug clinical trials
Gelonghui (688578.SH) announced on March 13, that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The phase I clinical study on the safety, tolerability, pharmacokinetics and initial efficacy of the self-developed AST2169 liposome for injection (known as “AST2169”) in patients with advanced solid tumors with KRAS G12D mutations was approved for drug clinical trials. AST2169 is a KRAS G12D selective inhibitor with global intellectual property rights independently developed by the company. KRAS G12D mutation
We Ran A Stock Scan For Earnings Growth And Shanghai Allist Pharmaceuticals (SHSE:688578) Passed With Ease
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
Alice (688578.SH) performance report: 2023 net profit of 645 million yuan, a year-on-year increase of 394.07%
Glonghui, Feb. 23 | Alice (688578.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved total operating revenue of 2,012 billion yuan, an increase of 154.42%; net profit attributable to owners of the parent company was 645 million yuan, an increase of 394.07% year on year; net profit attributable to owners of the parent company after deducting non-recurring profit and loss was 600 million yuan, an increase of 655.79% year on year. The above is mainly due to the sales revenue of the company's product vometinib mesylate tablets (trade name “Avsha”) of 1,972 billion yuan during the reporting period.
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Market Cap Dropped CN¥1.1b Last Week; Private Companies Bore the Brunt
Key Insights Shanghai Allist Pharmaceuticals' significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public The top 4 shareholders own
Tang Yu Investment, shareholder of Alice (688578.SH), completed a 2.34% reduction in shares
Zhitong Finance App News, Alice (688578.SH) announced that the company's shareholder Jiaxing Tang Yu Investment Partnership (Limited Partnership) (“Tang Yu Investment”) has reduced its holdings of the company's shares by a total of 10.514,700 shares through centralized bidding transactions and bulk transactions, accounting for 2.34% of the company's total share capital. The time range for this holdings reduction plan has expired.
Alice (688578.SH): ArriVent, the company's overseas partner, was successfully listed on NASDAQ on January 26
Gelonghui, January 29丨Alice (688578.SH) said on the investor interactive platform that the company's overseas partner ArriVent was successfully listed on the US NASDAQ on January 26, 2024 (US Eastern Time). For specific shareholding information, please refer to ArriVent's public prospectus. The company is honored to witness the successful launch of ArriVent. The company will continue to work closely with ArriVent to explore the potential for more differentiated indications of vometinib and continue to expand more opportunities for in-depth cooperation in the product pipeline.
Alice (688578.SH): First-line treatment indications for vometinib mesylate tablets EGFR20 exon insertion mutation NSCLC were included in the proposed breakthrough treatment category
Gelonghui, January 8, 丨 Elis (688578.SH) announced that the company's core product, vormetinib mesylate tablets (trade name “Avexar”, “vometinib” for short), was recently included in the publication list of proposed breakthrough therapeutic varieties by the Drug Evaluation Center of the State Drug Administration. The proposed indications are for use in locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with exon insertion mutations in EGFR 20. The publication period is January 8, 2024 to January 15, 2024.
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Shareholders Might Be Looking For Exit
When close to half the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or "P/S") below 3.7x, you may consider Shanghai Allist Pharmaceuticals Co., Ltd. (SHSE:688578) as
Alice (688578.SH): Vometinib mesylate tablets renewed and included in the national health insurance catalogue
<国家基本医疗保险、工伤保险和生育保险药品目录 (2023年) >Gelonghui (688578.SH) announced that on December 13, 2023, the website of the National Medical Security Administration published the “Notice on Issuance by the Ministry of Human Resources and Social Security of the National Health Insurance Administration”. The company's product fumetinib mesylate tablets (trade name “Iversha”, hereafter “fumetinib”) were successfully renewed and included in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2023)”. Vometinib mesylate tablets are a type of epidermal growth factor receptor tyrosine
Alice (688578.SH) shareholder Tang Yu Investment's shareholding fell below 5%
Alice (688578.SH) announced that the company received 5% of the company's shares on December 11, 2023...
Is Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Most readers would already be aware that Shanghai Allist Pharmaceuticals' (SHSE:688578) stock increased significantly by 27% over the past three months. Since the market usually pay for a company's
CICC: Maintaining Heyo-B's “Outperform Industry” rating, target price of HK$6.76
CICC released a research report stating that it maintains Heyo-B (02256) “outperforms the industry” rating, and the target price for 2023 remains unchanged at HK$6.76 in its profit forecast. The company recently announced a number of developments in products such as ABSK021 (CSF-1R inhibitor), including active clinical data updates for TGCT at the CTOS annual meeting, initiation of phase II clinical administration for pancreatic cancer, and more clinical progress of early pipeline molecules. CICC's main views are as follows: ABSK021 was used for the TGCT phase Ib data update, and the response rate was further improved. According to the company's official website, A
Alice (688578.SH): 243 million restricted shares will be listed and distributed from December 4, accounting for 54.05% of the total share capital
Alice (688578.SH) announced that the restricted shares listed and distributed by the company this time are part of the company's initial public offering...
Analysis
Price Target
No Data
